Allogeneic peripheral blood hematopoietic stem cell transplantation for post-operatively treating acute non-lymphocytic leukemia patient complicated with renal cell carcinoma: one case report.
- Author:
Hai-Yan ZHU
1
;
Wan-Ming DA
;
Chun-Ji GAO
;
Xiao-Ping HAN
;
Shu-Hong WANG
;
Yu JING
;
Jian BO
;
Hai-jie JIN
;
Meng LI
Author Information
1. Department of Hematology, The General Hospital of PLA, Beijing 100853, China.
- Publication Type:Case Reports
- MeSH:
Adult;
Carcinoma, Renal Cell;
surgery;
therapy;
Graft vs Host Disease;
prevention & control;
Humans;
Kidney Neoplasms;
surgery;
therapy;
Leukemia, Myeloid, Acute;
therapy;
Male;
Neoplasms, Multiple Primary;
therapy;
Peripheral Blood Stem Cell Transplantation;
Postoperative Period;
Transplantation, Homologous
- From:
Journal of Experimental Hematology
2008;16(1):203-206
- CountryChina
- Language:Chinese
-
Abstract:
The aim of this study was to evaluate the safety and efficacy of allogeneic hematopoietic peripheral blood stem cell transplantation (allo-PBHSCT) for post-operative therapy of acute non-lymphocytic leukemia (ANLL) patient complicated with renal cell carcinoma (RCC). One ANLL patient complicated with RCC underwent an myeloablative HLA-identical relative allo-PBHSCT after RCC operation. The conditioning regimen consisted of total body irradiation, cyclophosphamide and cytarabine. Graft versus host disease (GVHD) prophylaxis regimen composed of cyclosporine A, myco-phenolate mofetil and short course of methotrexate. The results indicated that the patient achieved engraftment 16 days after transplantation with full donor-type chimerism detected by STR-PCR at 30 and 100 days after transplantation. No acute or chronic GVHD and any severe complication developed. As of March 2007, the patient remains without disease at follow-up of 44 months. In conclusion, allo-HSCT procedure is feasible and effective for post-operative therapy of ANLL patient complicated with RCC without severe toxicity.
